Martin Shkreli, the hedge fund manager-turned-pharmacological profiteer, rocketed into the national consciousness on the back of an astronomical drug price increase. Daraprim is a medicine used to treat toxoplasmosis, particularly in patients with HIV, and it can also sometimes work as an antimalarial. After Shkreli’s Turing Pharmaceuticals acquired the drug in 2015, Daraprim rose in price from 13.50 USD to 750 USD. In November, some high-school aged students in Sydney, Australia, synthesized an equivalent drug, at an estimated cost of just $2 a dosage.